Status:
COMPLETED
A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients
Lead Sponsor:
Janssen Korea, Ltd., Korea
Conditions:
Schizophrenia
Eligibility:
All Genders
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.
Detailed Description
This is an open-label (all people know the identity of the intervention), multi-center, prospective (look forward using observations collected following participant enrollment), non-comparative, non-r...
Eligibility Criteria
Inclusion
- Participants diagnosed with schizophrenia
- Participants prescribed with paliperidone palmitate for acute or maintenance treatment
Exclusion
- Participants who received paliperidone palmitate for other than the approved indication
Key Trial Info
Start Date :
May 23 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2019
Estimated Enrollment :
3267 Patients enrolled
Trial Details
Trial ID
NCT01819818
Start Date
May 23 2011
End Date
November 29 2019
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KyungKi, South Korea